Short-term stake in Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) increases 146.8%

0

Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) was the target of a significant increase in short-term interest in September. As of September 30, there was short interest totaling 983,300 shares, an increase of 146.8% from the total of 398,400 shares as of September 15. Based on an average daily volume of 1,000,000 shares, the short-term interest rate ratio is currently 1.0 day.

Fresenius Medical Care AG & Co. KGaA Stock down 2.2%

FMS opened at $12.84 on Thursday. The company has a quick ratio of 0.85, a current ratio of 1.18 and a debt ratio of 0.47. The company has a 50-day moving average price of $16.43 and a 200-day moving average price of $24.04. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $12.78 and a 12-month high of $36.08. The stock has a market capitalization of $7.52 billion, a price/earnings ratio of 8.18, a PEG ratio of 0.64 and a beta of 1.06.

Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) last announced its results on Thursday, July 28. The company reported EPS of $0.41 for the quarter, missing analyst consensus estimates of $0.45 per ($0.04). Fresenius Medical Care AG & Co. KGaA achieved a net margin of 4.42% and a return on equity of 6.70%. The company posted revenue of $5.07 billion for the quarter, versus $4.80 billion expected by analysts. Equity research analysts expect Fresenius Medical Care AG & Co. KGaA to post 1.5 earnings per share for the current year.

Institutional trading of Fresenius Medical Care AG & Co. KGaA

Hedge funds and other institutional investors have recently increased or reduced their stakes in the company. Tcwp LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA during the first quarter, valued at approximately $44,000. SRS Capital Advisors Inc. increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 36.0% in the first quarter. SRS Capital Advisors Inc. now owns 1,545 shares of the company worth $52,000 after buying 409 additional shares in the last quarter. Creative Financial Designs Inc. ADV purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter at a value of $67,000. GHP Investment Advisors Inc. purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter at a value of $72,000. Finally, Signaturefd LLC increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 26.4% in the first quarter. Signaturefd LLC now owns 2,190 shares of the company worth $74,000 after purchasing an additional 458 shares in the last quarter. 5.59% of the shares are held by hedge funds and other institutional investors.

A Wall Street analyst gives his opinion

Several brokerages have recently published reports on FMS. DZ Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a Friday, July 29 report. Jefferies Financial Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research report on Monday. Berenberg Bank lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from €76.70 ($78.27) to €57.95 ($59.13) in a Wednesday, August 10 report. Truist Financial lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating for the company in a Wednesday 22 research note. June. Finally, UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a Friday, July 29 research note. One equity research analyst gave the stock a sell rating, eight gave the company a hold rating and three gave the company a buy rating. According to MarketBeat, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Hold” and a consensus price target of $45.83.

Fresenius Medical Care AG & Co. KGaA Company Profile

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Read more

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and Fresenius Medical Care AG & Co. KGaA didn’t make the list.

While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Share.

Comments are closed.